DK3286317T3 - Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi - Google Patents
Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi Download PDFInfo
- Publication number
- DK3286317T3 DK3286317T3 DK16722076.3T DK16722076T DK3286317T3 DK 3286317 T3 DK3286317 T3 DK 3286317T3 DK 16722076 T DK16722076 T DK 16722076T DK 3286317 T3 DK3286317 T3 DK 3286317T3
- Authority
- DK
- Denmark
- Prior art keywords
- dyrophy
- duchenn
- dynamin
- muscle
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05005—Dynamin GTPase (3.6.5.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305615.5A EP3085785A1 (en) | 2015-04-22 | 2015-04-22 | Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy |
PCT/EP2016/059090 WO2016170162A1 (en) | 2015-04-22 | 2016-04-22 | Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3286317T3 true DK3286317T3 (da) | 2021-05-17 |
Family
ID=53005533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16722076.3T DK3286317T3 (da) | 2015-04-22 | 2016-04-22 | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi |
Country Status (10)
Country | Link |
---|---|
US (2) | US10822400B2 (da) |
EP (2) | EP3085785A1 (da) |
JP (1) | JP6791877B2 (da) |
CN (1) | CN107532169B (da) |
AU (1) | AU2016251973B2 (da) |
CA (1) | CA2983211A1 (da) |
DK (1) | DK3286317T3 (da) |
ES (1) | ES2869978T3 (da) |
PT (1) | PT3286317T (da) |
WO (1) | WO2016170162A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10947540B2 (en) * | 2016-11-29 | 2021-03-16 | Association Institut De Myologie | Allele-specific silencing therapy for Dynamin 2-related diseases |
WO2018115477A1 (en) * | 2016-12-23 | 2018-06-28 | Universite De Strasbourg | Dynamin 2 inhibitor for the treatment of myotonic dystrophy |
CN110475573A (zh) * | 2017-01-23 | 2019-11-19 | 新泽西鲁特格斯州立大学 | 用于减少肌脂蛋白表达以及预防和治疗肌营养不良症和心肌病的组合物及其使用方法 |
CN111902537A (zh) | 2018-01-15 | 2020-11-06 | Ionis制药公司 | Dnm2表达的调节剂 |
EP4215614A1 (en) * | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
EP4311546A1 (en) | 2022-07-26 | 2024-01-31 | Dynacure | Combination therapy for myopathies |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
EP2119783A1 (en) * | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
CN102203253B (zh) * | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
EP2714020A1 (en) * | 2011-05-27 | 2014-04-09 | MD Pharma AB | Novel treatments |
US20140221464A1 (en) | 2011-07-01 | 2014-08-07 | Board Of Regents, The University Of Texas System | Compositions and Methods for Treating Skeletal Myopathy |
EP2862928A1 (en) * | 2013-10-18 | 2015-04-22 | Université de Strasbourg | Dynamin 2 inhibitor for the treatment of centronuclear myopathies |
-
2015
- 2015-04-22 EP EP15305615.5A patent/EP3085785A1/en not_active Withdrawn
-
2016
- 2016-04-22 US US15/568,007 patent/US10822400B2/en active Active
- 2016-04-22 JP JP2017555366A patent/JP6791877B2/ja not_active Expired - Fee Related
- 2016-04-22 CN CN201680023491.9A patent/CN107532169B/zh not_active Expired - Fee Related
- 2016-04-22 DK DK16722076.3T patent/DK3286317T3/da active
- 2016-04-22 AU AU2016251973A patent/AU2016251973B2/en not_active Ceased
- 2016-04-22 PT PT167220763T patent/PT3286317T/pt unknown
- 2016-04-22 ES ES16722076T patent/ES2869978T3/es active Active
- 2016-04-22 WO PCT/EP2016/059090 patent/WO2016170162A1/en active Application Filing
- 2016-04-22 CA CA2983211A patent/CA2983211A1/en active Pending
- 2016-04-22 EP EP16722076.3A patent/EP3286317B1/en active Active
-
2020
- 2020-10-30 US US17/084,686 patent/US20210130447A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3286317A1 (en) | 2018-02-28 |
ES2869978T3 (es) | 2021-10-26 |
US10822400B2 (en) | 2020-11-03 |
JP2018518456A (ja) | 2018-07-12 |
AU2016251973B2 (en) | 2022-05-26 |
CN107532169A (zh) | 2018-01-02 |
JP6791877B2 (ja) | 2020-11-25 |
CA2983211A1 (en) | 2016-10-27 |
WO2016170162A1 (en) | 2016-10-27 |
CN107532169B (zh) | 2021-09-03 |
EP3286317B1 (en) | 2021-02-24 |
PT3286317T (pt) | 2021-05-18 |
EP3085785A1 (en) | 2016-10-26 |
US20180142008A1 (en) | 2018-05-24 |
AU2016251973A1 (en) | 2017-11-09 |
US20210130447A1 (en) | 2021-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283267A (en) | Inhibitors of menin–mll interaction | |
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
DK3442972T3 (da) | Bromdomænehæmmere | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
DK3524255T3 (da) | Sammensætning til behandling af acne | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
DK3571192T3 (da) | Jak1-selektive inhibitorer | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3612519T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
DK3286317T3 (da) | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
DK3408265T3 (da) | Terapeutiske forbindelser | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
DK3256466T3 (da) | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser |